Literature DB >> 23464812

Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.

Na Ye1, John L Neumeyer, Ross J Baldessarini, Xuechu Zhen, Ao Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23464812     DOI： 10.1021/cr300113a

Source DB:  PubMed          Journal:  Chem Rev        ISSN： 0009-2665            Impact factor:   60.622


× No keyword cloud information.
  18 in total

1.  Multicomponent Synthesis and Biological Evaluation of a Piperazine-Based Dopamine Receptor Ligand Library.

Authors:  Mattia Stucchi; Peter Gmeiner; Harald Huebner; Giulia Rainoldi; Alessandro Sacchetti; Alessandra Silvani; Giordano Lesma
Journal:  ACS Med Chem Lett       Date:  2015-06-23       Impact factor: 4.345

2.  Functional roles of T3.37 and S5.46 in the activation mechanism of the dopamine D1 receptor.

Authors:  Estefanía A Hugo; Bruce K Cassels; Angélica Fierro
Journal:  J Mol Model       Date:  2017-03-31       Impact factor: 1.810

3.  Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.

Authors:  Zhiqing Liu; Jing Ai; Xia Peng; Zilan Song; Kui Wu; Jing Zhang; Qizheng Yao; Yi Chen; Yinchun Ji; Yanhong Yang; Meiyu Geng; Ao Zhang
Journal:  ACS Med Chem Lett       Date:  2014-02-08       Impact factor: 4.345

Review 4.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

Review 5.  Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target.

Authors:  Na Ye; Bang Li; Qi Mao; Eric A Wold; Sheng Tian; John A Allen; Jia Zhou
Journal:  ACS Chem Neurosci       Date:  2018-12-20       Impact factor: 4.418

6.  Molecular mechanism of the wake-promoting agent TAK-925.

Authors:  Jie Yin; Yanyong Kang; Aaron P McGrath; Karen Chapman; Megan Sjodt; Eiji Kimura; Atsutoshi Okabe; Tatsuki Koike; Yuhei Miyanohana; Yuji Shimizu; Rameshu Rallabandi; Peng Lian; Xiaochen Bai; Mack Flinspach; Jef K De Brabander; Daniel M Rosenbaum
Journal:  Nat Commun       Date:  2022-05-25       Impact factor: 17.694

7.  Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.

Authors:  Jie Yin; Kerim Babaoglu; Chad A Brautigam; Lindsay Clark; Zhenhua Shao; Thomas H Scheuermann; Charles M Harrell; Anthony L Gotter; Anthony J Roecker; Christopher J Winrow; John J Renger; Paul J Coleman; Daniel M Rosenbaum
Journal:  Nat Struct Mol Biol       Date:  2016-03-07       Impact factor: 15.369

8.  Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.

Authors:  Zhao-Xiang Ren; Ya-Fei Zhao; Ting Cao; Xue-Chu Zhen
Journal:  Acta Pharmacol Sin       Date:  2016-07-04       Impact factor: 6.150

9.  Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity.

Authors:  Cynthia B Berry; Michael Bubser; Carrie K Jones; John P Hayes; James A Wepy; Charles W Locuson; J Scott Daniels; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Med Chem Lett       Date:  2014-07-09       Impact factor: 4.345

10.  Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists.

Authors:  Pingyuan Wang; Daniel E Felsing; Haiying Chen; Sweta R Raval; John A Allen; Jia Zhou
Journal:  ACS Med Chem Lett       Date:  2019-04-05       Impact factor: 4.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.